The use of trastuzumab (Herceptin®), a monoclonal antibody (mAb) blocking Her-2/neu downstream signaling and inducing antibody-dependent cellular cytotoxicity (ADCC), has significantly improved the survival rate of patients with Her-2/neu-positive carcinomas [2]. The gene discussed is ERBB2; the disease is carcinoma.